Evidence map›Paper›PMID 23871888›Full record

ArticleJournal of the American College of Cardiology2013

Protease-activated receptor-2 regulates the innate immune response to viral infection in a coxsackievirus B3-induced myocarditis.

Alice Weithauser, Peter Bobbert, Silvio Antoniak, Andreas Böhm, Bernhard H Rauch, Karin Klingel, Konstantinos Savvatis, Heyo K Kroemer, Carsten Tschope, Andrea Stroux and 5 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of the American College of Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Cytotoxic CD8Cells · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Alice WeithauserDepartment of Cardiology and Pneumology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Institute for Chemistry-Biochemistry, Freie Universität Berlin, Berlin, Germany.
Peter Bobbert
Silvio Antoniak
Andreas Böhm
Bernhard H Rauch
Karin Klingel
Konstantinos Savvatis
Heyo K Kroemer
Carsten Tschope
Andrea Stroux
Heinz Zeichhardt
Wolfgang Poller
Nigel Mackman
Heinz-Peter Schultheiss
Ursula Rauch
Charité - Universitätsmedizin Berlin · DEUniversität Greifswald · DEUniversity of North Carolina at Chapel Hill · USBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEUniversity of Tübingen · DEZimmer Biomet (Germany) · DE

Funding

Role of the Thrombin PAR-1 Pathway in Viral InfectionR01HL119523 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MACKMAN, NIGEL · 2013 to 2020
$3.0M
NHLBI NIH HHS R01 HL119523
6 · The paper itself

Abstract

objectivesThis study sought to evaluate the role of protease-activated receptor-2 (PAR2) in coxsackievirus B3 (CVB3)-induced myocarditis.

backgroundAn infection with CVB3 leads to myocarditis. PAR2 modulates the innate immune response. Toll-like receptor-3 (TLR3) is crucial for the innate immune response by inducing the expression of the antiviral cytokine interferon-beta (IFNβ).

methodsTo induce myocarditis, wild-type (wt) and PAR2 knockout (ko) mice were infected with 10(5) plaque-forming units CVB3. Mice underwent hemodynamic measurements with a 1.2-F microconductance catheter. Wt and PAR2ko hearts and cardiac cells were analyzed for viral replication and immune response with plaque assay, quantitative polymerase chain reaction, Western blot, and immunohistochemistry.

resultsCompared with wt mice, PAR2ko mice and cardiomyocytes exhibited a reduced viral load and developed no myocarditis after infection with CVB3. Hearts and cardiac fibroblasts from PAR2ko mice expressed higher basal levels of IFNβ than wt mice did. Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNβ expression in PAR2ko than in wt fibroblasts and reduced virus replication in PAR2ko fibroblasts was abrogated by neutralizing IFNβ antibody. Overexpression of PAR2 reduced the basal IFNβ expression. Moreover, a direct interaction between PAR2 and Toll-like receptor 3 was observed. PAR2 expression in endomyocardial biopsies of patients with nonischemic cardiomyopathy was positively correlated with myocardial inflammation and negatively with IFNβ expression and left ventricular ejection fraction.

conclusionsPAR2 negatively regulates the innate immune response to CVB3 infection and contributes to myocardial dysfunction. The antagonism of PAR2 is of therapeutic interest to strengthen the antiviral response after an infection with a cardiotropic virus.

Indexed as

Immunity, InnateAnimalsAntibodies, ViralBiopsyBlotting, WesternDisease Models, AnimalEnterovirus B, HumanEnterovirus InfectionsGene Expression RegulationImmunohistochemistryMaleMiceMice, Inbred C57BLMyocarditisMyocardiumReal-Time Polymerase Chain ReactionAntibodies, ViralReceptor, PAR-2RNAToll-Like Receptor 3activating peptideAPCARCCLCDchemokine ligandcluster of differentiationcoxsackievirus-adenovirus receptorcoxsackievirus B3CVB3DAFdecay-accelerating receptorDMEMdouble-stranded ribonucleic aciddsRNADulbecco modified Eagle mediumFBSfetal bovine serumHLhuman leukocyteIFNβIFNγILinterferon betainterferon-betainterferon gammainterleukinknockoutkoleft ventricular ejection fractionLVEFmessenger ribonucleic acidmock plasmidmRNAmyocarditisPAR2PBSPCRphosphate-buffered salinephospho-signal transducer and activator of transcription-1p.i.poly(I:C)polyinosinic: polycytidylic acidpolymerase chain reactionpost-infectionprotease-activated receptor 2protease-activated receptor-2P-Stat1pVitroTLRTNFαToll-like receptorToll-like receptor 3tumor necrosis factor-alphawild typewt

Identifiers

PMID23871888
PMCPMC4077621
OpenAlexW2026490300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.